NCT03064113View on ClinicalTrials.gov

Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Chronic Obstructive Pulmonary Disease, COPD

Interventions

DRUG

Placebo

DRUG

TD-4208 700 μg

DRUG

TD-4208 350 μg

DRUG

Ipratropium 500 μg

Trial Locations (1)

6021

P3 Research, Wellington

Sponsors

Lead Sponsor

Collaborators (1)

Theravance Biopharma

All Listed Sponsors

collaborator

Theravance Biopharma

INDUSTRY

lead

Mylan Inc.

INDUSTRY